Clinical expertise

Dr Brian Halliday specialises in inherited and acquired cardiomyopathy (heart muscle disease), heart failure, heart recovery, myocarditis, cardiac genetics and cardiovascular magnetic resonance.

He is an expert in treating the following conditions:


Dr Halliday is a consultant cardiologist at Royal Brompton and Harefield hospitals and a clinical senior lecturer and British Heart Foundation intermediate fellow at the National Heart and Lung Institute, Imperial College London.

He completed his undergraduate training at University of Edinburgh before moving to London to continue his clinical training at Royal Brompton and Harefield hospitals and St George’s Hospital. He was awarded his PhD in dilated cardiomyopathy in 2018 from Imperial College London as well as the National Heart and Lung Institute prize for the best thesis. In 2021 he received a grant from the European Society of Cardiology to complete a part-time MSc in Clinical Trials at the Nuffield Department of Public Health, University of Oxford.

He has won several major international and national awards for his research from organisations including the European Society of Cardiology and the American College of Cardiology. His research in cardiomyopathy has shaped current international practice guidelines.

He is part of the board of the British Society of Heart Failure and also a member of the society’s research committee. He is on the editorial board of the European Heart Journal and Circulation Cardiovascular Imaging.

He is an academic tutor for Imperial College London medical students and module lead on the cardiovascular intercalated BSc programme.


Dr Halliday’s research interests include:

  • dilated cardiomyopathy
  • clinical trials of therapies and strategies
  • myocardial recovery and heart failure remission
  • risk stratification for sudden cardiac death and selection of patients for implantable cardioverter defibrillators
  • treatment of early forms of dilated cardiomyopathy

His research interests focuses on improving the treatment of patients with cardiomyopathy at different stages of disease. He designed and conducted the British Heart Foundation (BHF)-funded TRED-HF trial and was first author of the primary publication in The Lancet. He presented the results at the Late Breaking Clinical Trial Sessions at the American Heart Association, 2018.

More recently he has received further funding from the BHF to perform a follow-on trial in patients with recovered dilated cardiomyopathy (TRED-HF-2), as well as a trial of a novel antioxidant (MitoQ) in patients with persistent dilated cardiomyopathy, as part of a prestigious BHF Intermediate Fellowship.